Testicular Cancer Drugs Market Size, Share and Global Trend By Type of Cancer (Seminoma, Non-Seminoma, Others), By Drug (Etoposide, Ifosfamide, Vinblastine, Bleomycin, Dactinomycin), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), and Regional Forecast, 2024-2032

Testicular cancer refers to the type of cancer that occurs in the testes or testicles, an important organ in the male reproductive system, responsible for the production of male sex hormones and sperms for the purpose of reproduction. When considered along with other forms of cancers, testicular cancer is relatively rarer, but the most common form of cancer in males of ages 15-35. Treatment of testicular cancer is highly probable, even when cancer has spread beyond the testicles. The symptoms of testicular cancer include a lump in either of the testes, heaviness in the scrotum, sudden accumulation of fluid in the scrotum, dull ache in groin or abdomen, discomfort or pain in the testes or scrotum and back pain.

The individuals at most risks of being diagnosed with testicular cancer include those with an undescended testicle, presence of familial history, abnormal testes development, males in younger age groups and especially white men in terms of race. Treatment of testicular cancer includes surgical procedures, chemotherapy, and radiation therapy. Due to the rising prevalence of almost all forms of cancer, it is anticipated that the testicular cancer drugs market will exhibit positive growth, due to its strong occurrence in men of younger age groups.

The global testicular cancer drugs market is anticipated to grow, owing to a number of factors such as increased prevalence of testicular cancers, increasing advancements in treatment of testicular cancers, good prognosis rates in early detection, increasing demand for preventive care leading to early diagnosis, highly curable nature of the disease and increasing awareness of testicular cancer. According to the American Society for Clinical Oncology (ASCO), it was estimated that in the U.S., in 2017, 9,310 men were diagnosed with testicular cancer and the average age of diagnosis was 33 and testicular cancer was also the most common form of cancer in the age group of 15-35. These trends combined with the other factors are expected to positively drive the market growth.

The factors limiting the growth of global testicular cancer drugs market include the associated side effects of the treatment options and lack of diagnosis in earlier stages of testicular cancer.

Key Players Covered

Some of the major companies that are present in the global testicular cancer drugs market are Bristol-Myers Squibb Company, Fresenius Kabi AG, Teva Pharmaceutical Industries Ltd, Pfizer Inc., H. Lundbeck A/S, Ziopharm Oncology, Inc, and others.

SEGMENTATION

Among the segmentation, bleomycin- etoposide-paclitaxel (BEP) in the drug segment is projected to hold a considerable share of the global testicular cancer drugs market due to higher adoption of this combination of drugs for the effective treatment of testicular cancer.

Key Insights

• Regulatory scenario for key countries
• Pipeline analysis
• Recent industry developments such as partnerships, mergers, and acquisitions
• Overview of prevalence/ incidence of testicular cancer by key countries
• Overview of new advances in R&D

Regional Analysis

North America accounts for the largest share in the global market due to the increasing prevalence of testicular cancer, established healthcare system, high medical expenditure, access to advanced treatment options, demand for preventive care by diagnostic examinations and greater awareness of testicular cancer. The Asia Pacific is the fastest emerging market due to increasing incidences of testicular cancer, large population pools, the younger male population in certain regions, increasing awareness, increasing access to advanced treatment options and increasing healthcare expenditure due to greater disposable incomes.

Key Industry Developments

As of August 2018, a clinical trial is in Phase II which is testing whether the Cyclin-Dependent Kinase Inhibitor PD 0332991 may stop the growth of the tumor cells of several types of cancers including testicular cancer by blocking some of the enzymes needed for the cell growth of these cancerous cells. The trial is currently being conducted by the Abramson Cancer Center of the University of Pennsylvania.